Infant Formula Legal War: Why A Chicago Judge Is Over The 'Trial-By-Video' Era
A federal judge slams the use of video depositions in a high-stakes bellwether trial, signaling a major turning point for Abbott and Mead Johnson.
By Foodie Pundit Newsroom - Published - Updated - Section: Policy Regulation

Key points
- Judge Rebecca Pallmeyer is demanding in-person testimony, rejecting the 'trial-by-video' trend in the Abbott/Mead Johnson MDL.
- The core of the litigation involves allegations that cow-milk-based formulas cause a deadly gut disease (NEC) in premature infants.
- The outcome could redefine 'failure to warn' standards for the entire food and beverage industry, increasing transparency costs for all operators.
The food and beverage industry is currently staring down one of the most significant product liability battles in recent memory. At the center of this storm are two titan manufacturers, Mead Johnson and Abbott Laboratories, who are navigating a massive Multidistrict Litigation (MDL) in the U.S. District Court for the Northern District of Illinois. This is not just another corporate disagreement over labeling or supply chains. This is a high-stakes legal confrontation regarding the safety of infant formula and its alleged link to a devastating gastrointestinal condition in premature infants.
For the uninitiated, an MDL is a special federal legal procedure designed to speed up the process of handling complex cases. When hundreds or thousands of people file similar lawsuits against the same defendants, the courts group them together for pretrial proceedings. The goal is efficiency, but the current atmosphere in the Chicago courtroom is anything but streamlined.
U.S. District Judge Rebecca Pallmeyer has recently voiced significant frustration over the way this bellwether trial is unfolding. A bellwether trial is essentially a test case, meant to help both sides gauge how a jury will react to the evidence. If the test case feels like a movie screening rather than a live trial, the legal impact is diluted.
The "tea" here is that the trial has become what the judge calls a "trial-by-video." Instead of expert witnesses and corporate executives taking the stand in person to answer tough questions, the courtroom has been filled with hours of pre-recorded video depositions. Judge Pallmeyer has gone on the record calling this development "disappointing."
She even warned the legal teams that she would not be willing to conduct another bellwether trial under these conditions unless the majority of witnesses are prepared to testify live in Chicago. This matters because the "human element" of a trial is where corporate accountability often lives or dies. When you are talking about the health of the most vulnerable consumers in our society, a grainy Zoom call from three years ago does not carry the same weight as a witness facing a jury in the flesh. Who's On The Hook
The defendants in this massive litigation are household names. Mead Johnson, a major player in the global nutrition space, and Abbott Laboratories, a diversified healthcare leader, are the primary targets. These companies produce a significant portion of the infant formula sold in the United States and globally. For years, their products have been the go-to for hospitals and neonatal intensive care units (NICUs).
On the other side of the v. are the plaintiffs, represented by families who claim that these specific cow-milk-based formulas caused their premature infants to develop Necrotizing Enterocolitis (NEC). NEC is a severe, often fatal, intestinal disease that primarily affects preemies. It causes intestinal tissue to die and can lead to systemic infections.
The legal teams representing these families are pushing for a narrative of corporate negligence, alleging that these manufacturers knew about the risks associated with cow-milk-based formula for premature babies but failed to provide adequate warnings. The corporate defendants, meanwhile, are standing by the safety of their products, likely arguing that formula is a life-saving necessity for infants who cannot receive human milk and that the causes of NEC are complex and multifactorial. The financial and reputational stakes for Abbott and Mead Johnson are astronomical, as these bellwether results will set the settlement temperature for thousands of pending cases. The Allegations Unpacked
To understand why this case is rocking the food science and legal worlds, we have to look at the science of the gut. The core allegation is that cow-milk-based infant formulas, when fed to premature infants, significantly increase the risk of developing NEC compared to an exclusive human milk diet.
Plaintiffs argue that the manufacturers have been aware of clinical studies for decades suggesting a link between bovine-based formula and NEC in the preterm population. The legal "gotcha" here is not just that the product might be risky, but that the companies allegedly downplayed those risks in their marketing and failed to include specific warnings on their packaging. In the world of food law, "failure to warn" is a heavy hitter. It implies that the consumer (or in this case, the medical professional and parent) was deprived of the information necessary to make an informed choice.
The defense strategy typically involves highlighting the essential nature of formula. Not every NICU has access to a reliable supply of donor human milk, and for many babies, these formulas are the primary source of calories and nutrients required for growth. Abbott and Mead Johnson are essentially arguing that their products are a vital tool in neonatal care and that the science does not definitively prove a causal link between their specific formulas and the onset of NEC, which can occur for a variety of biological reasons. Financial Fallout
While the specific settlement numbers remain under wraps for subscribers of high-end legal databases, we can look at the broader landscape to see the looming financial shadow. In previous product liability cases involving large-scale health issues, settlements have reached into the billions of dollars. For Mead Johnson and Abbott, a loss in these bellwether trials could trigger a "settlement wave" that would impact their bottom lines for a decade.
For investors and industry watchers, this is a red-flag moment. Legal fees alone for a multidistrict litigation of this scale are massive. When you add the potential for punitive damages, which are designed to punish a company for particularly egregious behavior, the numbers become staggering.
This isn't just about paying out a few claims; it is about the potential for a total restructuring of how infant nutrition is marketed and sold. If the courts decide that these products require black-box warnings, the market share for cow-milk-based preemie formula could collapse, forcing these giants to pivot their entire R&D and production strategies. Big Tobacco Parallels
There is a growing sentiment among legal scholars that the infant formula litigation shares DNA with the historic battles against Big Tobacco. In those cases, the argument wasn't just that the product was harmful, but that the companies knew the risks and actively worked to suppress that information while marketing the product as safe or even desirable.
In the formula MDL, the plaintiffs are painting a picture of a "marketing-first" culture that prioritized the ubiquity of formula in hospitals over the potential health outcomes of a specific, high-risk sub-population. Just as the tobacco industry faced a reckoning over what they knew and when they knew it, Abbott and Mead Johnson are being forced to open their internal archives. The discovery phase of these trials, where internal emails and memos are brought to light, is often where the most damaging evidence is found. If the plaintiffs can prove that internal scientists raised concerns that were silenced by marketing executives, the "Big Tobacco" comparison will become the defining narrative of the trial. What This Means For Independent Restaurants
You might be wondering: what does a trial about NICU formula have to do with a local bistro or a trendy coffee shop? The answer lies in the "ripple effect" of food safety regulation and consumer trust.
When a major sector of the food industry is hit with a massive liability suit, it usually leads to a tightening of FDA regulations across the board. Independent restaurant operators should prepare for increased scrutiny on all specialized food products, especially those marketed as "healthy" or "nutritionally complete." We could see a new era of labeling requirements that are more stringent, making it more expensive for small-scale producers to bring innovative food products to market.
Furthermore, these cases change the way consumers think about "processed" food. A Gen Z parent who sees headlines about formula-induced illness is going to be even more skeptical of the ingredients list at their local eatery. This creates a "transparency tax" for independent operators.
To keep the trust of a skeptical public, restaurants will need to be even more diligent about their supply chains and more transparent about where their ingredients come from. If the giants can't be trusted to get it right for babies, the average consumer will wonder what's actually in their "locally sourced" brunch. What Happens Next
The immediate future of the MDL depends on whether the legal teams heed Judge Pallmeyer's warning. The current "trial-by-video" format is clearly reaching a breaking point. We can expect a pivot toward more in-person testimony in upcoming bellwether trials as lawyers try to appease the court and, more importantly, win over the jury with live credibility.
Watch for the results of the next few test cases. If the juries return large verdicts in favor of the plaintiffs, Abbott and Mead Johnson will likely be forced to the settlement table to avoid a never-ending cycle of litigation. On the regulatory front, the FDA is undoubtedly watching these proceedings. Regardless of the legal outcome, the pressure to reform how infant formula is categorized and labeled is reaching a fever pitch.
For the food industry at large, the lesson is clear: transparency isn't just a marketing buzzword; it's a legal shield. The era of "trust us, we're a big corporation" is officially over. Whether you are a multi-billion dollar lab or a small-town kitchen, the responsibility to warn, to vet, and to be honest about the risks of your product is the new industry standard. We'll be watching the Chicago courtroom closely to see if the "video era" of law ends, and if a new era of corporate accountability begins.
Stay tuned, because this case is far from its final course. The gut health of a generation and the financial stability of two food giants hang in the balance. In the world of food law, the recipe for disaster is often written in the fine print, and the court is finally reading it out loud.
Sources and methodology
Reported from the public datasets below.